Fusion Pharmaceuticals (FUSN.US): The 2024 Q1 financial report achieved revenue of $0, previous value of USD 28,000, expected value of USD 150,000; earnings per share was -0.40 USD, previous value of -0.45 USD, and expected value of -0.37 USD.
Fusion Pharmaceuticals(FUSN.US)：2024年Q1财报实现营收0美元，前值为2.8万美元，预期值为15万美元；每股收益为-0.40美元，前值为-0.45美元，预期值为-0.37美元。
Fusion Pharmaceuticals (FUSN.US): The 2024 Q1 financial report achieved revenue of $0, previous value of USD 28,000, expected value of USD 150,000; earnings per share was -0.40 USD, previous value of -0.45 USD, and expected value of -0.37 USD.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.